Compare Regeneron Pharmaceuticals Inc (REGN) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52 (market cap $114.40B). The key difference: iShares 0 3 Month Treasury Bond ETF is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares 0 3 Month Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and iShares 0 3 Month Treasury Bond ETF for 50 Days on average.
| REGN | SGOV | |
|---|---|---|
Market Cap | $76.14B | $114.40B |
Volume | 500,239 | 18,879,081 |
Sector | Health | Fixed Income |
52-Week High | $852.03 | $100.72 |
52-Week Low | $557.73 | $100.28 |
Typical Hold Time | 107 Days | 50 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.47 with minimal daily price movement, reflecting its ultra-short-term Treasury bond focus. The technical picture shows bearish momentum with moving averages signaling caution, while oscillators remain neutral. Recent corporate actions include consistent dividend distributions around $0.30-0.31 per share through mid-2026.
As a Treasury bond ETF, SGOV offers low volatility and regular income but faces headwinds from rising interest rates. The fund provides exposure to short-term government debt with minimal credit risk, though higher yields elsewhere may pressure returns. Current bond market volatility creates both challenges and opportunities for short-term fixed income investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
